Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
156 Cannabis Trials Near You
Power is an online platform that helps thousands of Cannabis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerTHC for Cannabis Use
Los Angeles, California
The purpose of this research is to assess the effects of smoked cananbis when cannabis is smoked during periods of cannabis use as usual and after a brief period of abstinence.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:21 - 55
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Psychiatric Illness, Pregnancy, Others
Must Not Be Taking:Prescription Analgesics, Others
30 Participants Needed
Vaping Device Labeling for Nicotine and Cannabis Use
Los Angeles, California
This study assesses how the ways in which nicotine and cannabis vaping devices are labeled impact use susceptibility, anticipated effects, and health harm.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:11 - 19
Key Eligibility Criteria
Disqualifiers:Cognitive Impairment, Others
3900 Participants Needed
Smoked Cannabis Effects Study
Los Angeles, California
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:21 - 55
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Axis I, Others
Must Not Be Taking:Illicit Drugs, Others
22 Participants Needed
CBG + THC for Pain
Los Angeles, California
This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:21 - 55
Key Eligibility Criteria
Disqualifiers:Moderate-severe CUD, Axis I Disorder, Others
Must Not Be Taking:Any Medications
20 Participants Needed
Terpenes + THC for Pain
Los Angeles, California
The purpose of this research is to assess the analgesic and subjective effects of terpenes administered alone and in combination of THC.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:21 - 55
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Hypertension, Pregnancy, Others
Must Not Be Taking:Prescription Analgesics
45 Participants Needed
Cannabis for Pain Relief
Los Angeles, California
This trial is studying the effects of smoking cannabis on pain relief and potential abuse in men and women. Researchers are comparing how different doses affect each sex and how their bodies process THC, the active ingredient in cannabis. The goal is to understand if there are significant differences between men and women in these effects.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:21 - 55
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Severe Psychiatric Illness, Others
Must Not Be Taking:Medical Cannabis, Prescription Analgesics
160 Participants Needed
Dronabinol Effects on THC Metabolism During Pregnancy
Seattle, Washington
Cannabis use is prevalent among pregnant women, but the effects of use on both the developing fetus and pregnant woman are unknown. Importantly, drug exposure could be influenced by the impact of pregnancy-associated hormones on the metabolism of tetrahydrocannabinol (THC), the main psychoactive component of cannabis. The goal of this study is to determine whether cortisol and estradiol - hormones that rise dramatically during pregnancy - increase the clearance of dronabinol (THC) in reproductive age women to simulate the pregnant state. The collected data will then be used to predict the time course and magnitude of changes in THC metabolism in pregnant women, particularly with gradually increasing estradiol and cortisol concentrations that evolve over the course of pregnancy. The overall objective of this study is to better understand the effects of THC use during pregnancy on the health of the pregnant woman and developing fetus.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:21 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Cardiac, Cancer, Others
Must Not Be Taking:Anticoagulants, Antipsychotics, Antidepressants, Others
12 Participants Needed
Communication Skills for Cannabis Use
Seattle, Washington
The objectives of this research is to (1) create a family intervention and provider manual to train family members of young people with psychosis (YP-P) who are heavy cannabis users new communication skills to motivate change in the YP-P's cannabis use, (2) pre-test the intervention with 10 family member participants and adapt the intervention based on their recommendations, and (3) evaluate the feasibility and acceptability of the intervention in a randomized pilot trial (n=40). The investigators anticipate that the intervention will improve family participants' communication skills, decrease expressed emotion and caregiver burden. The investigators anticipate that improvements in communication skills, expressed emotion and caregiver burden will lead to decreases in the cannabis use of their YP-P.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Non-English Speakers, No Zoom Access
40 Participants Needed
Prazosin for Cannabis Use Disorder
Seattle, Washington
Cannabis use disorder (CUD) is a significant and expanding health problem, and no FDA approved treatments are currently available. Persons with posttraumatic stress disorder (PTSD) may use cannabis to help control symptoms. Relief from PTSD insomnia, nightmares, anxiety, and preoccupying thoughts have been reported as troublesome symptoms targeted by cannabis users. Risks from cannabis use by individuals with PTSD have been reported. Chronic use of cannabis can lead to tolerance, requiring increased use for symptom relief, and withdrawal symptoms upon stopping. CUD is more frequent and severe in those with PTSD than those without. Many symptoms of cannabis withdrawal overlap with troubling symptoms of PTSD and thus may be interpreted as a relapse of PTSD symptoms. Those attempting to reduce or stop cannabis use may experience cannabis withdrawal symptoms including insomnia and distressing dreams, anxiety, irritability, and/or excessive sweating that they may misattribute to re-emerging or untreated PTSD symptoms.
Excessive brain adrenaline activity is arguably the best-described neurobiological contribution to the pathophysiology of PTSD. Prazosin, a drug that blocks the negative effects of brain adrenaline, has demonstrated effectiveness in robustly reducing PTSD-related nightmares and sleep disturbance in active duty Servicemembers and recently discharged combat Veterans in most, but not all, clinical trials, as well as in civilians with non-combat trauma. Clinically, the investigators have observed that several patients with PTSD using cannabis to treat insomnia and/or trauma-related nightmares and wanting to reduce their cannabis use were able to achieve reduction or cessation of cannabis use once they were treated with an effective dose of prazosin. Therefore, we have wondered if prazosin may provide sufficient treatment of PTSD symptoms otherwise targeted by cannabis, supporting those individuals' efforts to reduce cannabis use.
This open-label pilot study aims to study the feasibility of prazosin as a treatment for CUD in individuals with or without comorbid PTSD, and to evaluate if additional research on a larger scale is warranted.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Cognitive Disorder, Severe TBI, Others
Must Not Be Taking:Synthetic Cannabinoids, Trazodone
20 Participants Needed
THC (Dronabinol) for Sleep Issues in Cannabis Users
Portland, Oregon
The investigators will test the effects of 10-60mg dronabinol (oral THC) on sleep in non-frequent and frequent cannabis users.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:21 - 34
Key Eligibility Criteria
Disqualifiers:Not Listed
18 Participants Needed
Cannabis Oil Adjunct for Opioid Use Disorder
Vancouver, British Columbia
This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:25+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Respiratory Disease, Psychotic Disorders, Others
Must Be Taking:Methadone
24 Participants Needed
Cannabis Consumption for Driving Impairment
Sacramento, California
In a true experiment, roughly 300 volunteer participants will smoke active cannabis, a corresponding placebo, or no substance at all (control). Next, participants will complete a drive test and then be observed by actual California Highway Patrol (CHP) officers who will attempt to classify participants as impaired or unimpaired. CHP Officers will evaluate participants in the context of driving (i.e., while following participants in an actual patrol car), as part of a roadside behavioral assessment (i.e., the Advanced Roadside Impaired Driving Enforcement, or ARIDE, battery, which includes Standardized Field Sobriety Tests, or SFSTs), and as part of a Drug Recognition Expert (DRE) evaluation conducted indoors.
Trial Details
Trial Status:Recruiting
Age:21 - 55
Key Eligibility Criteria
Disqualifiers:Not Listed
300 Participants Needed
Cannabis Awareness and Prevention Toolkit for Reducing Youth Cannabis Use
Palo Alto, California
The Stanford Tobacco Prevention Toolkit is a free, online Toolkit that consists of a curriculum, educational resources, and a resource directory to be used by educators, parents, juvenile justice workers, and healthcare providers to increase knowledge and awareness of cannabis and reduce use among youth. The aim of this study is to investigate the extent to which the curriculum changes students' intentions to use and actual use of cannabis.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:10 - 20
Key Eligibility Criteria
Disqualifiers:Not Listed
600 Participants Needed
Reduced-THC Cannabis for Cognitive Impairment from Cannabis Use
San Francisco, California
The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25.
The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to baseline?
Other questions this study aims to answer include:
* Can researchers accurately assess THC consumption among frequent cannabis users?
* Can researchers effectively incentivize cannabis users to use less potent THC products?
* Do genetic variations in THC metabolism impact urinary THC excretion?
* Do genetic variations in THC metabolism impact cognitive performance in cannabis users?
* Are quantitative urinary THC values predictive of cognitive impairment?
* How can researchers use research findings to inform harm reduction practices for people who use cannabis?
Participants will submit blood and urine samples and be incentivized to use less potent THC products.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 25
Key Eligibility Criteria
Disqualifiers:Pregnant, Regular Drug Use, Others
110 Participants Needed
Vaporized Cannabis + Nicotine for Cannabis and Tobacco Use
San Francisco, California
This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:21 - 65
Key Eligibility Criteria
Disqualifiers:Heart Disease, Cancer, Diabetes, Schizophrenia, Others
Must Not Be Taking:Anticonvulsants, Stimulants, Nicotine Medications
48 Participants Needed
Cannabis for Heart Rhythm Issues
San Francisco, California
Despite recreational cannabis now being legal in 23 states, where more than 100 million Americans reside, studies on the actual health effects are limited. This study is a randomized trial, where each participant will be instructed to consume or avoid cannabis on randomly assigned days during a 14-day monitoring period. The goal of this study is to answer the question:
"Does cannabis use increase the frequency of 'early' and abnormal heart beats?"
During the 14-day period, participants will wear an external heart monitor, a glucose monitor, and a fitness tracker to track heart rhythm, glucose levels, step counts, and sleep health. Participants will use a mobile app or a text messaging service for daily instructions/reminders on cannabis use, and short surveys. The investigators ask that participants smoke or vape cannabis at least once on days they are instructed to consume cannabis. Compelling evidence of heart and other health effects would be important to the clinical care of our patients.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Atrial Fibrillation, Heart Failure, Others
Must Not Be Taking:Anti-arrhythmics
100 Participants Needed
Secondhand Cannabis Smoke Exposure for Healthy Subjects
San Francisco, California
This is an unblinded pilot study of an environmental exposure to secondhand cannabis smoke in one group of healthy nonsmokers.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:21 - 50
Key Eligibility Criteria
Disqualifiers:Asthma, Heart Disease, Hypertension, Diabetes, Others
Must Not Be Taking:Cannabis, CBD, THC, Others
200 Participants Needed
N-Acetylcysteine for Substance Use Disorder
San Francisco, California
This trial tests NAC, a medication and supplement, to help adults who use both tobacco and cannabis reduce their cravings. NAC works by calming overactive brain signals and reducing stress, making it easier to control cravings. N-acetylcysteine (NAC) has been tested in previous trials for cannabis use disorder, showing mixed results in efficacy.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Psychotic Disorders, Bipolar, Pregnancy, Others
Must Not Be Taking:NAC, NRT, Bupropion, Varenicline
59 Participants Needed
Mobile Intervention for Alcohol and Marijuana Use
Honolulu, Hawaii
The goal of this treatment development project is to develop an adaptive ecological momentary intervention (a-EMI) for young adults using marijuana and alcohol that is grounded in self-regulation and social cognitive theories. To determine the most efficacious intervention strategies, the investigators will test variations of intervention components to identify the best combination. The study will take place at the Center for Integrated Health Care Research at Kaiser Permanente Hawaii (KPHI), located in Honolulu (island of Oahu). Following pilot testing with 6 participants, the study team will assess the feasibility and efficacy of intervention components on two primary outcomes (negative consequences and protective behavioral strategies \[PBS\]) using a fractional factorial experimental design, with post-intervention assessment and one- and three-month follow-ups. 136 diverse young adults recruited from KPHI who report current simultaneous alcohol and marijuana (SAM) use will be randomly assigned to one of eight groups, representing experimental conditions that include or do not include intervention strategies focused on craving reduction and PBS. As a result of this process, individual and/or combined components that lead to improved outcomes will be retained in a subsequent randomized controlled trial, while ineffective components will be eliminated.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 30
Key Eligibility Criteria
Disqualifiers:Substance Use Treatment, Others
136 Participants Needed
Cannabidiol for Chronic Liver Injury Prevention
West Chester, Ohio
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:1+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Liver Fibrosis, Hepatitis, Others
Must Be Taking:Epidiolex
154 Participants Needed
Why Other Patients Applied
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
Epidiolex for Tuberous Sclerosis Complex
Cincinnati, Ohio
This trial investigates how adding EPIDIOLEX to existing treatments affects behavior and other outcomes in people aged 1 to 65 with TSC who have seizures. The medication aims to reduce seizure frequency and severity by influencing brain chemicals. Epidiolex, a cannabidiol (CBD) product, has been studied for its safety and effectiveness in treating seizures related to tuberous sclerosis complex (TSC).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:1 - 65
Key Eligibility Criteria
Disqualifiers:Unstable Medical Condition, Tumor Growth, Others
Must Be Taking:Anti-seizure Medicines
79 Participants Needed
Cannabidiol for Seizures
Cincinnati, Ohio
This trial tests a medication called GWP42003-P in children under 2 years old who have severe seizure disorders like TSC, LGS, or DS. The study will last over a year and will check if the medication is safe, how it moves through the body, and if it helps reduce seizures. These conditions often don't respond well to usual treatments, so new options are needed. Cannabidiol (pharmaceutical) is approved by the FDA for the treatment of seizures associated with DS, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients ≥1 year of age.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Age:1 - 23
Key Eligibility Criteria
Disqualifiers:Not Listed
27 Participants Needed
CardiolRx for Pericarditis
Cleveland, Ohio
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation.
Double-blind treatment will be initiated 10 - 14 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks.
The objective is to assess whether patients who discontinue therapy with an IL-1 blocker for recurrent pericarditis remain free of pericarditis recurrence while receiving CardiolRx.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Cancer, Sepsis, Myocarditis, Others
Must Be Taking:IL-1 Blockers
110 Participants Needed
Cannabidiol for Driving Performance
Morgantown, West Virginia
The objectives/purpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using a rigorous RCT design which will naturally mitigate confounding factors.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 30
Key Eligibility Criteria
Disqualifiers:Tobacco, Illegal Drugs, Pregnancy, Others
Must Not Be Taking:Daily Prescriptions
300 Participants Needed
Cannabidiol + Morphine for Chronic Pain
Detroit, Michigan
The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana.
Trial Details
Trial Status:Recruiting
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Not Listed
40 Participants Needed
CBD for Chronic Pain
Ann Arbor, Michigan
This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain.
Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period.
The study hypotheses:
- CBD would improve overall pain symptoms compared to placebo
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Suicidal Ideation, Neurological Disorders, Others
Must Not Be Taking:Valproate, Clobazam
468 Participants Needed
CBD + THC for Multiple Sclerosis Symptoms
Ann Arbor, Michigan
The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Severe Depression, Schizophrenia, Cardiovascular, Others
Must Not Be Taking:Cannabinoids, Warfarin, Valproate, Others
166 Participants Needed
CBD + THC for Knee Osteoarthritis
Ann Arbor, Michigan
This clinical trial is being done to better understand how daily treatment with Tetrahydrocannabinol (THC), Cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms.
Consented participants will have a screening period and visit (up to 30 days to treatment start). If participants pass the screening phase, they will be randomly assigned to take one of the investigational study drugs. For this study, participants will not know when or if they are taking CBD, THC, THC plus CBD, and when or if taking placebo.
Clinical pain will be assessed at multiple times throughout the study, and eligibility will be re-assessed at two weeks into the treatment period. It is possible that subjects will not be able to participate in the study after 14 days of of treatment. The treatment period will take approximately 16 weeks and then a follow-up period for approximately 2 weeks. In addition to treatment, participants will have clinical assessments, blood draws, questionnaires, daily pain diaries, sensory testing, as well as have functional connectivity magnetic resonance imaging (fcMRI).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 75
Key Eligibility Criteria
Disqualifiers:Severe Cardiovascular Disease, Epilepsy, Liver Failure, Others
Must Not Be Taking:Opioids, Valproate, Clobazam, Warfarin
200 Participants Needed
Cannabidiol + Tacrolimus for Transplant Rejection
Indianapolis, Indiana
This trial aims to understand how CBD, a cannabis compound, interacts with tacrolimus, a drug used by organ transplant patients to prevent rejection. Researchers will study these interactions to see if CBD affects the safety and effectiveness of tacrolimus. Tacrolimus is a strong medication used to prevent organ rejection in transplant patients, with precise dosing requirements. The goal is to help doctors adjust doses of both substances to improve patient health and long-term treatment success.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Seizure Disorder, Liver Dysfunction, Others
Must Not Be Taking:Sedatives, Immunosuppressants, CYP3A4/5 Inhibitors
72 Participants Needed
Cannabidiol for Bipolar Depression
Hamilton, Ontario
This trial is testing CBD, a chemical from the cannabis plant, to see if it can help people with bipolar depression who haven't responded to standard treatments. CBD might work by balancing brain chemicals that influence mood.
Stay on current meds
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:19 - 70
Key Eligibility Criteria
Disqualifiers:Rapid Cycling, Psychotic Disorders, Others
Must Be Taking:Mood Stabilizers, Atypical Antipsychotics
360 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do Cannabis clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Cannabis clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Cannabis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Cannabis is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Cannabis medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Cannabis clinical trials?
Most recently, we added Digital Intervention for Depression and Cannabis Use, THC Vaping Liquids for Cannabis Use and Cannabis for Cognitive Impairment to the Power online platform.
Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.